NZ722879B2 - A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc) - Google Patents

Abstract

1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of renal cell carcinoma (RCC).

Description

(12) Granted patent specificaon (19) NZ (11) 722879 (13) B2 (47) Publicaon date: 2021.12.24 (54) A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE FOR THE USE FOR THE TREATMENT OF RENAL CELL CARCINOMA (RCC) (51) Internaonal Patent ficaon(s): A61K 31/506 A61P 35/00 (22) Filing date: (73) Owner(s): 2014.12.16 MERCK PATENT GMBH (23) Complete specificaon filing date: (74) Contact: 2014.12.16 HENRY HUGHES IP D (30) aonal Priority Data: (72) Inventor(s): EP 14000036.5 2014.01.07 BLADT, Friedhelm FRIESE-HAMIM, Manja (86) Internaonal Applicaon No.: 2014/003365 (87) Internaonal Publicaon number: WO/2015/104042 (57) Abstract: 3-(1-{3-[5-(1-methyl-piperidinylmethoxy)-pyrimidinyl]-benzyl}6-oxo-1,6-dihydro-pyridazin yl)-benzonitrile or a pharmaceucally acceptable salt and/or solvate thereof for the use for the treatment of renal cell carcinoma (RCC).

NZ 722879 B2 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (RCC) FIELD OF THE INVENTION This invention relates to 3-(1-{3-[5-(1-methyl-piperidin—4-ylmethoxy)-pyrimidin- 2-yl]—benzy|}—6—oxo-1,6-dihydro-pyridazinyl)—benzonitrile or a pharmaceutically acceptable salt and/or solvate f for the use for the ’IO treatment of renal cell carcinoma (RCC), preferably for the use for the treatment of ary renal cell carcinoma (pRCC).

BACKGROUND OF THE INVENTION The invention had the object of finding novel pharmaceutical compositions having valuable properties, in particular those which can be used for the preparation of medicaments.

Moreover, aim of this invention are new compositions for the tion and treatment of hepatocellular carcinoma.

It has been found that 3-(1-{3—[5—(1-methyl-piperidin-4—ylmethoxy)-pyrimidin yl]-benzyl}oxo-1,6-dihydro-pyridazinyl)—benzonitrile according to the invention or a pharmaceutically acceptable salt and/or solvate thereof has very valuable cological ties while being well tolerated.

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. Renal cell carcinoma (RCC, formerly known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that transport GF rular filtrate) from the glomerulus to the descending limb of the nephron. RCC is the most common type of kidney cancer in adults, responsible for approximately 80% of cases. It has been described as being initial treatment is most among the most lethal of all the urological cancers. commonly a radical or partial ctomy and remains the mainstay of curative treatment. Where the tumor is confined to the renal parenchyma, the -year al rate is , but this is lowered considerably where metastases have spread. A special type of RCC is pRCC (papillary renal cell carcinoma).

Activation of the c-Met pathway occurs in a range of malignancies, including RCC. Published studies indicate that c-Met is associated with poor pathologic features and sis in RCC and especially in papillary renal cell carcinoma (pRCC).

RCC is curable only in patients presenting with able, early-stage disease. Advanced local or metastatic disease carries an approximate 15% 5- of metastatic RCC is year survival rate. However, the natural history heterogeneous, and aggressive palliative ent is recommended, especially for patients with a solitary metastatic site and good performance status. se rates to cytokine therapy remain generally less than 25%, and complete responses are rare. To improve these results, combinations of biologics with and without cytotoxic chemotherapy are being investigated.

Here we demonstrate that the Met kinase inhibitor 3-(1-{3-[5—(1—methyl- dinylmethoxy)—pyrimidInyl]—benzyl}—6-oxo-1 ,6-dlhyd ro—pyridazin-S-y|)-. . benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof is active in RCC, preferably in pRCC.

PRIOR ART 3—[5—(1-Methyl-piperidinylmethoxy)-pyrimidinyl]—benzyl}-6—oxo—1 ,6- dihydro-pyridazin—3-yl)-benzonitrile has been described in A1. 3-(1-{3-[5-(1-Methyl-piperidinylmethoxy)-pyrimidinyl]-benzyl}oxo-1,6- dihydro-pyridazinyl)-benzonitrile hydrochloride hydrate has been described in WO 07074 A1.

SUMMARY OF THE INVENTION The present ion particularly provides for aspects and embodiments as set out in the clauses below: 1. Use of 3-(1-{3-[5-(1-methyl-piperidinylmethoxy)-pyrimidinyl]-benzyl} 6-dihydro-pyridazinyl)-benzonitrile hydrochloride hydrate for the manufacture of a medicament for the treatment of renal cell carcinoma (RCC). 2. The use according to clause 1, wherein, the 3-(1-{3-[5-(1-methyl-piperidin ylmethoxy)-pyrimidinyl]-benzyl}oxo-1,6-dihydro-pyridazinyl)- benzonitrile hydrochloride hydrate is 3-(1-{3-[5-(1-methyl-piperidin ylmethoxy)-pyrimidinyl]-benzyl}oxo-1,6-dihydro-pyridazinyl)- benzonitrile hydrochloride monohydrate. 3. The use according to clause 1 or 2, wherein the treatment comprises administration of an amount of 100 mg to 800 mg of the compound to a t per day. 4. The use according to any one of clauses 1 to 3, wherein the treatment ses oral administration of the nd.

. The use according to any one of clauses 1 to 4, wherein renal cell oma (RCC) is papillary renal cell carcinoma (pRCC).

Moreover, the invention relates to 3-(1-{3-[5-(1-methyl-piperidinylmethoxy)- pyrimidinyl]-benzyl}oxo-1,6-dihydro-pyridazinyl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of renal cell carcinoma (RCC), preferably for the use for the treatment of papillary renal cell carcinoma (pRCC). - 3a - Moreover, the invention relates to 3-(1-{3-[5-(1-methyl-piperidinylmethoxy)- pyrimidinyl]-benzyl}oxo-1,6-dihydro-pyridazinyl)-benzonitrile hydrochloride hydrate for the use for the treatment of renal cell oma (RCC), preferably for the use for the treatment of papillary renal cell carcinoma (pRCC).

Moreover, the invention relates to 3-(1-{3-[5-(1-methyl-piperidinylmethoxy)- pyrimidinyl]-benzyl}oxo-1,6-dihydro-pyridazinyl)-benzonitrile or a pharmaceutically able salt and/or solvate thereof, wherein the nd is administered to a patient in an amount of 100 mg to 800 mg per day.

Moreover, the invention relates to 3-(1-{3-[5-(1-methyl-piperidinylmethoxy)- pyrimidinyl]-benzyl}oxo-1,6-dihydro-pyridazinyl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof, wherein the nd is administered orally.

Moreover, the invention relates to the use of 3-(1-{3-[5-(1-methyl-piperidin oxy)-pyrimidinyl]-benzyl}oxo-1,6-dihydro-pyridazinyl)- benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the manufacture of a medicament for the treatment of renal cell carcinoma (RCC), preferably for the use for the treatment of papillary renal cell carcinoma . Moreover, the invention relates to the use. of 3—(1-{3-[5-(1-methyl- piperidinylmethoxy)—pyrimidinyl]—benzy|}—6—oxo—1,6-dihydro—pyridazinyl)— benzonitrile hydrochloride hydrate for the manufacture of a medicament for the treatment of renal cell carcinoma (RCC), preferably for the use for the treatment of papillary renal cell carcinoma (pRCC).

Moreover, the invention relates to the use as described above, n 3—(1-{3-[5—(1—methyl—piperidin—4-ylmethoxy)—pyrimidinyl]—benzyl} oxo-1,6-dihydro-pyridazinyI)-benzonitrile or a ceutically acceptable salt and/or solvate thereof or 3-(1-{3-[5-(1-methy|—piperidin-4—yI-methoxy)-pyrimidin-2—yI]-benzyl}oxo-1 ,6- dihydro-pyridazinyl)—benzonitrile hydrochloride hydrate, wherein the compound is administered to a patient in an amount of 100 mg to 800 mg per day, preferably in an amount of 200 mg to 700 mg per week, particularly preferably in an amount of 250 mg to 350 mg per day. er, the ion s to the use as described above, wherein 3-(1—{3—[5-(1-methy|—piperidin-4—ylmethoxy)—pyrimidinyl]—benzyI} oxo-1,6—dihydro-pyridazin—3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof or 3—(1-{3—[5-(1—methyI—piperidinylmethoxy)—pyrimidin—2-yl]—benzy|}oxo—1 ,6— dihydro-pyridaziny|)-benzonitrile hydrochloride hydrate wherein the compound is administered orally.

The therapy with 3-(1-{3-[5—(1—methy|—piperidin-4—ylmethoxy)-pyrimidin—2—y|]- benzyl}oxo—1,6-dihydro—pyridazin—3—yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof or 3-(1-{3-[5-(1-methy|—piperidin—4-ylmethoxy)—pyrimidinyl]—benzyl}—6—oxo-1 ,6— dihydro-pyridazin-3—yl)-benzonitrile hydrochloride e may include optionally further treatment with radiation. The invention relates rmore to of 3-(1-{3-[5-(1- a new therapy form sing the start of the administration methyl—piperidin—4—ylmethoxy)-pyrimidinyI]—benzyI}—6-oxo-1,6—dihydro- pyridazinyI)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof prior to radiotherapy for the treatment of renal cell carcinoma (RCC), preferably for the use for the ent of papillary renal cell carcinoma (pRCC).

The invention also s to the optically active forms (stereoisomers), and solvates enantiomers, the racemates, the diastereomers and the hydrates of the compound.

The invention also relates to the solvates of the salts of the compound e.g. mono- or dihydrate of the hydrochloride. 1O The term solvates of the compound is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.

The expression "effective amount” denotes the amount of a medicament or of in a tissue, system, animal or a pharmaceutical active ingredient which causes human a biological or medical se which is sought or desired, for example, by a researcher or ian.

In addition, the expression "therapeutically ive amount” denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequence: improved treatment, g, prevention or elimination of a e, syndrome, condition, complaint, disorder or side-effects or also the reduction in the advance of a disease, complaint or disorder.

The expression "therapeutically effective amount” also encompasses the amounts which are effective for increasing normal physiological function.

The said compounds according to the ion can be used in their final non— salt form. On the other hand, the t ion also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of 3-(1— {3~[5—(1-methyl-piperidinylmethoxy)-pyrimidin—2-yl]-benzy|}—6—oxo-1 ,6— WO 04042 2014/003365 dihydro-pyridazinyl)—benzonitrile and N—((S)—2,3-dihydroxy—propyl)—3—(2— fluoro-4—iodo-phenylamino)-isonicotinamide are for the most part prepared by conventional methods.

If a compound contains a carboxyl group, one of its suitable salts can be formed by ng the compound with a le base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal ides, such as barium hydroxide and 1O calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. The aluminium salts of the compounds are likewise included. In the case of certain compounds acid-addi- tion salts can be formed by treating these compounds with pharmaceutically acceptable organic and nic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen , other mineral acids and corresponding salts thereof, such as sulfate, nitrate or ate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and esulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid—addition salts of the compounds e the following: e, adipate, alginate, arginate, aspartate, benzoate, benzene- sulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentane- nate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecyl- sulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturo- nate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemi— succinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, , isethionate, iso- te, lactate, lactobionate, , maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphos— phate, 2—naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not ent a restriction.

Furthermore, the base salts of the nds according to the invention include aluminium, ammonium, calcium, copper, iron(lll), iron(ll), lithium, magnesium, manganese(lll), manganese(ll), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above—men— tioned salts, preference is given to ammonium; the alkali metal salts sodium 1O and potassium, and the alkaline earth metal salts calcium and magnesium.

Salts of the compounds which are derived from pharmaceutically acceptable organic xic bases include salts of primary, secondary and tertiary amines, tuted , also including naturally occurring substituted amines, cyclic amines, and basic ion ger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'—dibenzylethylenediamine (benzathine), dicyclohexylamine, dieth'anolamine, diethylamine, 2-diethyl- aminoethanol, 2-dimethylaminoethanol, lamine, nediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, ine, lysine, meglumine, N-methyl-D- glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, pyl- amine and ydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction.

Compounds of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C1-C4)alkyl halides, example methyl, ethyl, isopropyl and utyl chloride, bromide and iodide; di(C1—C4)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C10— C1e)alkyl halides, for example decyl, dodecyl, lauryl, yl and stearyl chloride, bromide and iodide; and aryl(C1-C4)alkyl halides, for example benZyl chloride and hyl bromide. Both water— and oil-soluble compounds according to the invention can be prepared using such salts.

W0 2015/104042 - 8 _ The above—mentioned pharmaceutical salts which are preferred include acetate, oroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, e, oleate, onate, pivalate, sodium phosphate, stearate, e, sulfosalicylate, tartrate, late, tosylate and tromethamine, but this is not intended to represent a restriction.

Particular preference is given to hydrochloride, dihydrochloride, hydrobromide, maleate, mesylate, phosphate, sulfate and succinate.

The acid—addition salts of basic compounds are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain al properties, such as lity in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

As mentioned, the pharmaceutically able base-addition salts of the compounds are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N’- dibenzylethylenediamine, chloroprocaine, choline, nolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The base—addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner.

The free acid can be rated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms W0 2015/104042 - g _ differ in a certain t from the corresponding salt forms thereof with respect to n physical properties, such as lity in polar solvents; for the purposes of the invention, however, the salts othen/vise correspond to the respective free acid forms thereof.

With regard to that stated above, it can be seen that the expression "phar- maceutically acceptable salt” in the present connection is taken to mean an active ingredient which comprises a compound in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic ty which it did not have r and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic cy in the body.

The invention furthermore relates to medicaments comprising at least one compound and/or pharmaceutically acceptable salts, es, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or nts.

Pharmaceutical formulations can be administered in the form of dosage units which comprise a ermined amount of active ingredient per dosage unit.

Such a unit can comprise, for example, 0.5 mg to 1 9, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a nd according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part—dose, as indicated above, or a corresponding fraction thereof of an active ingredient. rmore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art.

Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including , sublingual or transdermal), vaginal or parenteral ding aneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the ent(s) or adjuvant(s).

Pharmaceutical formulations adapted for oral administration can be adminis- tered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or sions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in—oil liquid emulsions.

Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active—ingredient component can be ed with an oral, non— toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, ol, water and the like. Powders are ed by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.

Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells ith. Glidants and lubricants, such as, for example, highly se silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium ate, may likewise be added in order to improve the availability of the medicament after the capsule has been taken.

In addition, if desired or necessary, suitable binders, lubricants and disin- Suitable ts as well as dyes can se be incorporated into the mixture. binders include , gelatine, natural sugars, such as, for example, glucose l and synthetic rubber, or beta-lactose, sweeteners made from maize, such as, for example, acacia, tragacanth or sodium alginate, carboxymethyl- cellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The egrants include, without being restricted thereto, starch, methylcellulose, and the like. The s are formulated by, for agar, bentonite, xanthan gum example, ing a powder e, granulating or dry-pressing the mixture, adding a ant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in and optionally a suitable manner with a diluent or a base, as described above, with a binder, such as, for example, carboxymethylcellulose, an te, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for e, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or ons of cellulose or polymer materials and pressing. it through a sieve. As an alternative to granulation, the powder mixture can be run h a tabletting machine, giving lumps of iform shape, which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds.

The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings order to be able to differentiate between different dosage units.

Oral liquids, such as, for e, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity ses a ecified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable r, while s are prepared using can be formulated by dispersion of a non-toxic alcoholic vehicle. Suspensions the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour ves, such as, for example, peppermint oil or l ners or saccharin, or other artificial sweeteners and the like, can likewise be added.

The dosage unit formulations for oral administration can, if desired, be en- capsulated in microcapsules. The formulation can also be prepared in such a extended or retarded, such as, for example, by coating way that the release is and the like. or embedding of particulate material in polymers, wax The compounds and salts, solvates, tautomers and stereoisomers thereof can also be administered in the form of liposome delivery s, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, terol, stearylamine or phosphatidylcholines.

The compounds and the salts, solvates, tautomers and stereoisomers thereof individual carriers to can also be delivered using onal dies as which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl— methacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene W0 2015/104042 _ 13 _ oxide polylysine, substituted by palmitoyl radicals. The compounds may which are furthermore be coupled to a class of biodegradable rs suitable for achieving controlled e of a medicament, for example polylactic acid, psilon-caprolactone, polyhydroxybutyric acid, poly- orthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogelsf Pharmaceutical formulations adapted for transdermal administration can be 1O administered as ndent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).

Pharmaceutical compounds adapted for topical administration can be for- mulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, ls or oils.

Pharmaceutical formulations adapted for rectal stration can be ad- ministered in the form of suppositories or enemas.

Pharmaceutical formulations d for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.

Pharmaceutical ations adapted for administration by inhalation encom— which can be ted by various types pass finely particulate dusts or mists, of pressurised dispensers with aerosols, nebulisers or insufflators. 2014/003365 Pharmaceutical formulations d for parenteral administration include solutions comprising antioxidants, aqueous and non—aqueous sterile injection buffers, bacteriostatics and s, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in —dose or multidose containers, for example sealed es and vials, and stored in freeze-dried (Iyophilised) state, so that only the addition of the sterile carrier 1O liquid, for example water for injection purposes, immediately before use is in accordance with necessary. Injection solutions and suspensions prepared the recipe can be prepared from sterile powders, granules and s.

It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, for— mulations which are suitable for oral administration may comprise flavours.

A therapeutically effective amount of a compound depends on a number of factors, including, for example, the age and weight of the animal, the precise ion that requires ent, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. r, an effective amount of a compound according to the invention is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and ularly lly in the range from 1 to mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part— doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt, solvate, tautomer and stereoisomer thereof can be determined as the fraction of the ive amount of the compound according to the invention per se. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.

The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the composition of the invention, conventional surgery or radiotherapy.

"Treating" as used herein, means an alleviation, in whole or in part, of symptoms associated with a disorder or disease, or g, or halting of r progression or ing of those symptoms, or prevention or prophylaxis of the disease or disorder in a subject at risk for developing the disease or disorder.

The term "effective amount" in connection with a compound can mean an amount capable of alleviating, in whole or in part, symptoms associated with a disorder or disease, or slowing or halting further progression or worsening of those symptoms, or preventing or ing prophylaxis for the disease or disorder in a subject having or at risk for ping a disease disclosed herein, such as cancer, The term “therapeutically ive” or “therapeutically effective amount” refers to an amount of a drug effective to treat a e or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell ration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth and/or kill ng cancer cells, it may be cytostatic and/or cytotoxic.

For cancer y, efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).

W0 2015/104042 _ 15 _ 3-(1—{3-[5-(1—methyl—piperidin—4-ylmethoxy)—pyrimidin-2—yl]-benzyl}—6-oxo-1 ,6- dihydro-pyridazinyl)-benzonitrile hydrochloride hydrate is suitable as pharmaceutical active ingredient for mammals, especially for humans, in the treatment of renal cell carcinoma (RCC), preferably for the use for the treatment of papillary renal cell carcinoma (pRCC). mental Evaluation of 3-(1-{3-[5-(1—methyl—piperidin—4—ylmethoxy)—pyrimidin-2—yl]- benzyl}—6-oxo-1,6-dihydro—pyridazinyl)-benzonitrile hydrochloride hydrate in preclinical RCC models. To this end several t—derived tumor models were obtained: 786-0 (ATCC CRL-1932) Human Primary renal cell adenocarcinoma A-498 (ATCC HTB—44) Human Papillary, epidermoid kidney carcinoma Caki—1 (ATCC HTB-46) Human Kidney carcinoma CAKl-2 (DSM ACC 54) Human Kidney carcinoma G-401 (ATCC CRL 1441) Human a rhabdoid tumor of the kidney G—402 (ATCC CRL 1440) Human Kidney Leiomyoblastoma SK-NEP-1 (ATCC HTB-48) Human Ewing sarcoma SN12A1 (NCl vial 0502750) Human renal carcinoma 786-0: The renal carcinoma cell line 786-0 was established from a primary renal cell adenocarcinoma of a 58 year old male ian patient. The cells y both microvilli and omes, and can be grown in soft agar.

Previous studies have shown that the 786-0 cell line harbors an inactivating mutation in the von-Hippel Lindau (VHL) gene.

A-498: The kidney oma A-498 was established from the kidney IEF of AST, carcinoma of a 52—year-old man in 1973 med as human with MDH, NP.

Caki-1: The Caki-1 cell line was established in 1971 from a metastatic site (skin) in a 49-year—old ian male with clear cell carcinoma of the kidney.

Caki—1 is a human clear cell renal cell carcinoma ) line that displays epithelial morphology and grows in adherent culture. When grown on transwell the apical filters, these cells form a polarized monolayer with microvilli on e and display characteristic features of the proximal tubule epithelium. In addition, the Caki-1 cells are also a useful model to study renal cancer. They inhibitor of are more sensitive to 5-fluorouracii and sorafenib (multi-kinase VEGFR8 1-3, PDGFR-b and Raf—1) than the Caki—2 cells. The Caki-1 cells and are express wildtype von Hippei-Lindau (VHL) tumor-suppressor protein known to form tumors in immunocompromised mice.

Caki-2: This cell line derived from a 69 year old Caucasian male with a kidney carcinoma. The cells contain microfilaments and multilaminar bodies. They also exhibit microvilli. Recent evaluation (K. Pulkkanen and J. en, personal communication) of nude mouse tumors formed by this line in orthotopic and 5.0. implantations were consistent with cystic papillary renal cell carcinoma according to the criteria of Kovacs et ai.. (5-401: Derived from a tumour of a 3 month old male Caucasian. Highiy transformed and grows in soft agar. Highly undifferentiated. G401 was originally described as a cell line derived from a Wilms tumour. Due to a 3O change in the fication of such tumours, the cell line was examined by Garvin et al., 1993 and found to be more appropriately classified as derived from a rhabdoid tumour of the kidney. (3-402: This cell line was established from a tumour of a 9 month old female Caucasian. Highly transformed and grows in soft agar. The tumors formed by W0 2015/104042 _ 18 _ classified as derived from this cell line in immune compromised mice were human Caucasian renal leiomyoblastoma of the kidney.

SK—NEP-1: By gene expression profiling it was demonstrated that SK-NEP-1, a is instead cell line previously thought to ent anaplastic Wilms tumor, EWS- related to Ewing a. RT-PCR med that SK-NEP—1 expresses FL|1 gene fusion transcripts characteristic of Ewing sarcoma, and sequencing demonstrated the g of exon 7 of EWS with exon 5 of FLl1 for these transcripts.

: This tumor cell line derived from a tumor tissue that was obtained in a 43-year— from a primary renal tumor subsequent to a radical nephrectomy old male. The tumor was diagnosed as a renal" cell carcinoma with extensive invasion of perinephric fat.

After reproducing the growth of these tumor models in immune—compromised mice 3-(1-{3-[5-(1—methyl-piperidinylmethoxy)-pyrimidinyl]-benzyl}-6—oxo- 1,6-dihydro—pyridazinyl)—benzonitrile hydrochloride hydrate was evaluated in models with acceptable take rate.

Patent

Claims (6)

Claims

1. Use of 3-(1-{3-[5-(1-methyl-piperidinylmethoxy)-pyrimidinyl]- benzyl}oxo-1,6-dihydro-pyridazinyl)-benzonitrile hydrochloride hydrate for the manufacture of a medicament for the treatment of renal cell carcinoma (RCC).

2. The use according to claim 1, wherein, the 3-[5-(1-methylpiperidinylmethoxy )-pyrimidinyl]-benzyl}oxo-1,6-dihydropyridazinyl )-benzonitrile hydrochloride hydrate is 3-(1-{3-[5-(1- methyl-piperidinylmethoxy)-pyrimidinyl]-benzyl}oxo-1,6- dihydro-pyridazinyl)-benzonitrile hydrochloride monohydrate.

3. The use ing to claim 1 or 2, wherein the treatment comprises administration of an amount of 100 mg to 800 mg of the compound to a patient per day.

4. The use according to any one of claims 1 to 3, wherein the treatment comprises oral administration of the compound.

5. The use according to any one of claims 1 to 4, wherein renal cell carcinoma (RCC) is papillary renal cell oma (pRCC).

6. A use according to claim 1 substantially as herein bed or exemplified.